Higher glutamate + glutamine and reduction of N-acetylaspartate in posterior cingulate according to age range in patients with cognitive impairment and/or pain

Academic Radiology

Volumn 21, Issue 9, 2014, Pages 1211-1217

  Fayed, Nicolás ^a   Andrés, Eva ^b   Viguera, Laura ^a   Modrego, Pedro J ^c   Garcia Campayo, Javier ^c  

^a Division of Dermatology Quiron Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Cognitive impairment; Magnetic resonance spectroscopy; Pain; Posterior cingulate cortex voxel

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; N ACETYLASPARTIC ACID; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS CALLOSUM; CORRELATION ANALYSIS; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROMETER; PAIN; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SOMATIZATION; SOMATOFORM DISORDER; TRIGEMINUS NEURALGIA; VERY ELDERLY; AGE; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; CINGULATE GYRUS; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASPARTIC ACID; CASE-CONTROL STUDIES; COGNITION DISORDERS; CREATINE; FEMALE; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES;

EID: 84905561784     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2014.04.009     Document Type: Review

References (56)

1. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008, 1124:1-38.
2. Lustig C., Snyder A.Z., Bhakta M., et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A 2003, 100:14504-14509.
3. Greicius M.D., Srivastava G., Reiss A.L., et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004, 101:4637-4642.
4. Lui F., Duzzi D., Corradini M., et al. Touch or pain? Spatiotemporal patterns of cortical fMRI activity following brief mechanical stimuli. Pain 2008, 138:362-374.
5. Raichle M.E., MacLeod A.M., Snyder A.Z., et al. A default mode of brain function. Proc Natl Acad Sci U S A 2001, 98:676-682.
6. Jorge L.L., Amaro E. Brain imaging in fibromyalgia. Curr Pain Headache Rep 2012, 16:388-398.
7. Sheline Y.I., Barch D.M., Price J.L., et al. The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A 2009, 106:1942-1947.
8. Kennedy D.P., Redcay E., Courchesne E. Failing to deactivate: resting functional abnormalities in autism. Proc Natl Acad Sci U S A 2006, 103:8275-8280.
9. Bluhm R.L., Miller J., Lanius R.A., et al. Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network. Schizophr Bull 2007, 33:1004-1012.
10. Antuono P.G., Jones J.L., Wang Y., et al. Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1) H-MRS at 0.5 T. Neurology 2002, 56:737-742.
11. Fayed N., Modrego P.J., Rojas-Salinas G., et al. Glutamate is decreased in Alzheimer's disease. A magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen 2011, 26:450-456.
12. Hattori N., Abe K., Sakoda S., et al. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002, 13:183-186.
13. Rupsingh R., Borrie M., Smith M., et al. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 2009, 32:802-810.
14. Harris R.E., Sundgren P.C., Craig A.D., et al. Elevated insular glutamate (Glu) in fibromyalgia (FM) is associated with experimental pain. Arthritis Rheum 2009, 60:3146-3152.
15. Fayed N., Garcia-Campayo J., Magallón R., et al. Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 2010, 12:R134.
16. Fayed N., Andres E., Rojas G., et al. Brain dysfunction in fibromyalgia and somatization disorder using proton magnetic resonance spectroscopy: a controlled study. Acta Psychiatr Scand 2012, 126:115-125.
17. Harris R.E. Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther 2010, 12:141.
18. Provencher S.W. Estimation of metabolite concentrations from localised in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679.
19. Vogt B.A. Regions and subregions of the cingulate cortex. Cingulate neurobiology and disease 2009, 3-30. Oxford University Press, New York, NY. B.A. Vogt (Ed.).
20. Fayed N., Modrego P.J., Medrano J. Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software. Neurol Res 2009, 31:472-477.
21. Williamson L.C., Neale J.H. Calcium-dependent release of N-acetyl aspartyl glutamate from retinal neurons upon depolarization. Brain Res 1988, 475:151-155.
22. Cassidy M., Neale J.H. N-acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface of neurons and glia. Neuropeptides 1993, 24:271-278.
23. Ross B.D., Blüml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001, 265:54-84.
24. Petroff O.A.C., Mattson R.H., Rothman D.L. Proton MRS: GABA and glutamate. Adv Neurol 2000, 83:261-271.
25. Bejjani A., O'Neill J., Kim J., et al. Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI. PLoS One 2012, 7:e38786.
26. Escartin C., Valette J., Lebon V., et al. Neuron-astrocyte interactions in the regulation of brain energy metabolism: a focus on NMR spectroscopy. J Neurochem 2006, 99:393-401.
27. Cooper J.R., Bloom F.E., Roth R.H. The biochemical basis of neuropharmacology 2000, Oxford University Press, Oxford, UK. 8th ed.
28. Gracely R.H., Petzke F., Wolf J.M., et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2000, 46:1333-1343.
29. Buckley P.F., Moore C., Long H., et al. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol Psychiatry 1994, 36:792-800.
30. Modrego P.J., Fayed N., Pina M.A. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005, 162:667-675.
31. Zahr N.M., Mayer D., Pfefferbaum A., et al. Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy. Cereb Cortex 2008, 18:2241-2250.
32. Javitt D.C., Schoepp D., Kalivas P.W., et al. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011, 3:102mr2.
33. Fayed N., Dávila J., Oliveros A., et al. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol 2008, 15:1089-1098.
34. Baslow M.H. The vertebrate brain, evidence of its modular organization and operating system: insights in to the brain's basic units of structure, function, and operation and how they influence neuronal signaling and behavior. Front Behav Neurosci 2011, 5:5.
35. Alexander G.E., Chen K., Pietrini P., et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002, 159:738e45.
36. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimers disease. Ann Nucl Med 2001, 15:85-92.
37. Londono A.C., Castellanos F.X., Arbelaez A., et al. An 1H-MRS framework predicts the onset of Alzheimer's disease symptoms in PSEN1 mutation carriers. Alzheimers Dement 2013, Nov 13.
38. Targosz-Gajniak M.G., Siuda J.S., Wicher M.M., et al. Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. J Neurol Sci 2013, 335:58-63.
39. Tumati S., Martens S., Aleman A. Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis. Neurosci Biobehav Rev 2013, 37(10 Pt 2):2571-2586.
40. Kantarci K. Magnetic resonance spectroscopy in common dementias. Neuroimaging Clin N Am 2013, 23:393-406.
41. Salek R.M., Xia J., Innes A., et al. A metabolic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 2010, 56:937-947.
42. Parnetti L., Lowenthal D.T., Presciutti O., et al. 1 H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J Am Geriatr Soc 1996, 44:133-138.
43. Kantarci K., Xu Y.C., Shiung M.M., et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2002, 14:198-207.
44. Aoki Y., Inokuchi R., Suwa H. Reduced N-acetylaspartate in the hippocampus in patients with fibromyalgia: a meta-analysis. Psychiatry Res 2013, 213:242-248.
45. Fairhurst M., Wiech K., Dunckley P., et al. Anticipatory brainstem activity predicts neural processing of pain in humans. Pain 2007, 128:101-110.
46. Ziv M., Tomer R., Defrin R., et al. Individual sensitivity to pain expectancy is related to differential activation of the hippocampus and amygdala. Hum Brain Mapp 2010, 31:326-338.
47. González de la Aleja J., Ramos A., Mato-Abad V., et al. Higher glutamate to glutamine ratios in occipital regions in women with migraine during the interictal state. Headache 2013, 53:365-375.
48. Siniatchkin M., Sendacki M., Moeller F., et al. Abnormal changes of synaptic excitability in migraine with aura. Cereb Cortex 2012, 22:2207-2216.
49. Reyngoudt H., Achten E., Paemeleire K. Magnetic resonance spectroscopy in migraine: what have we learned so far?. Cephalalgia 2012, 32:845-859.
50. Cacace AT, Silver SM. Applications of magnetic resonance spectroscopy to tinnitus research: initial data, current issues, and future perspectives. B. Langguth, G. Hajak, T. Kleinjung, et al (Eds.) Progress in Brain Research 2007; Vol. 166; CHAPTER 7; ISSN 0079-6123 Copyright Elsevier B.V.
51. Gutzeit A., Meier D., Froehlich J.M., et al. Differential NMR spectroscopy reactions of anterior/posterior and right/left insular subdivisions due to acute dental pain. Eur Radiol 2013, 23:450-460.
52. Miller A.K., Corsellis J.A. Evidence for a secular increase in human brain weight during the past century. Ann Hum Biol 1977, 4:253-257.
53. Kaiser L.G., Schuff N., Cashdollar N., et al. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol Aging 2005, 26:665-672.
54. Resnick S.M., Pham D.L., Kraut M.A., et al. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 2003, 23:3295-3301.
55. Angelie E., Bonmartin A., Boudraa A., et al. Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. AJNR Am J Neuroradiol 2001, 22:119-127.
56. Chang L., Ernst T., Poland R.E., et al. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 1996, 58:2049-2056.